Generic Name

norethindrone acetate transdermal

Brand Names
CombiPatch, Junel
FDA approval date: August 07, 1998
Classification: Progestin
Form: Patch, Tablet

What is CombiPatch (norethindrone acetate transdermal)?

CombiPatch is indicated in a woman with a uterus for: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.

Brand Information